Navigation Links
BioMS Medical announces third quarter 2007 results
Date:11/14/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 14 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the third quarter, ended September 30, 2007.

"During the quarter, we continued to maintain momentum towards the commercialization of our lead drug, MBP8298, for the treatment of multiple sclerosis," said Kevin Giese, President and CEO of BioMS Medical.

Third Quarter 2007 Highlights:

- The independent Data Safety Monitoring Board (DSMB) for MINDSET-01,

the Company's on-going phase II trial of MBP8298 for relapsing-

remitting MS, completed a safety analysis and recommended that the

trial continue as per protocol. This double blind phase of this trial

is expected to complete in the second half of 2008.

- Subsequent to the end of the quarter,

- Two posters presented at the 23rd Congress of the European

Committee for Treatment and Research in Multiple Sclerosis

(ECTRIMS) in Prague, Czech Republic, in respect of the phase

III MAESTRO-01 secondary progressive MS (SPMS) study, showed

that over 70% of the screened patients had the drug's target

HLA DR2 and/or DR4 responder genes, and that an interim

analysis showed no significant safety concerns with the drug.

An interim safety and efficacy analysis for MAESTRO-01 is

planned for mid-2008.

- The Company announced that the U.S. pivotal phase III SPMS

trial, MAESTRO-03, is on track for full enrollment in 2008, and

completed enrollment of the first 133 patients who will form

the basis of an interim analysis that is expected in 2009.

Financial Results

The consolidated net loss for the three months ended
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
6. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
7. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
8. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
9. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
10. ATS Medical Expands Open Pivot Heart Valve Offerings
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  The full interim results will be presented ... and IGF Society, being held October 15-18, 2014, ...
(Date:9/16/2014)... September 16, 2014 BCC Research ... FOR STEM CELLS , the global market for stem ... by 2018, with a five-year compound annual growth rate ... in the Americas with growth projections of $2.2 billion ...      (Logo: http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other potential ...
(Date:9/16/2014)... 2014 RENU 28, the world's first and ... available for purchase in Australia and New Zealand in mid-August ... September 16th. The tour will make stops in Brisbane on ... the 18th, Sydney on the 20th, and Melbourne on the ... New Zealand and to educate people about the new product ...
(Date:9/15/2014)... , Sept. 15, 2014   Global Science ... of scientific products and services for satellite and ... Solution for Integrated Services (OASIS) from the General ... was selected to provide the government best-value solutions ... Business (SB) category in Pool 4. The OASIS ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3
... Biomerica,Inc. (OTC Bulletin Board: BMRA) has introduced a ... announced that it received CE mark approval to,market and ... in,the European Union. The product will be marketed under ... people in the U.S. are allergic to cat dander,the ...
... 18 Forest Laboratories, Inc.,(NYSE: FRX ) and ... the novel beta,blocker Bystolic(TM) (nebivolol) was approved by the ... hypertension. Bystolic is a once,daily medication that can be ... affects approximately 72 million,adults in the U.S. and 65 ...
... Using the latest methods for nanofabrication, a team led ... electronic property in one of the earliest-known and most-studied ... magnetite. , By changing the voltage in their experiment, ... than minus 250 degrees Fahrenheit to revert from an ...
Cached Biology Technology:Biomerica Introduces a New 15 Minute Home Test for Allergies to Cats and Receives CE Mark Approval for Home Use 2Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 2Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 3Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 4Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 5New property found in ancient mineral lodestone 2
(Date:9/16/2014)... is associated with increased rates and intensity of tobacco ... the relationship between schizophrenia and smoking stems, in part, ... self-medicate symptoms and cognitive impairment associated with the disease. ... of Biological Psychiatry , sheds light on this ... receptors in the brain was lower in schizophrenia patients ...
(Date:9/16/2014)... responsible for practically all vital functions in an ... signals, transport particular substances and control immune system ... do not function independently of each other, but ... the protein networks, you find many similarities with ... TUM,s Chair of Plant Systems Biology. "Some proteins ...
(Date:9/15/2014)... Human skin and gut microbes influence processes from digestion ... are the most biodiverse terrestrial ecosystems on the planet, ... trees in the tropics. Smithsonian scientists and colleagues working ... samples from a single tree were home to more ... from 57 tree species contained more than 7,000 different ...
Breaking Biology News(10 mins):Smoking and schizophrenia linked by alterations in brain nicotine signals 2Good networkers make prime targets 2Smithsonian scientists discover tropical tree microbiome in Panama 2
... study was conducted by researchers from Scripps Research; the ... Taiwan University. It is being published today in the ... Chi-Huey Wong is currently the Ernest W. Hahn Chair ... and directs the Scripps Research lab heading the study. ...
... is your goal, you can't do better than to emulate ... and an unusual pitching stroke that allows the bug to ... is a marvel of engineering. , Z. Jane Wang, professor ... research on flying systems and fluid dynamics today (Feb. 19) ...
... mention the cleaning product industry, repeatedly warn of their ... is raising the intriguing idea that persistent bacterial and ... Robert W. and Vivian K. Cahill Professor in Cancer ... an essay in the Feb. 24 issue of the ...
Cached Biology News:Enzyme inhibitors block replication of SARS virus 2Scientist uses dragonflies to better understand flight 2Scientists look to the Bahamas as a model for coral reef conservation 2Scientists look to the Bahamas as a model for coral reef conservation 3
... clone d1-174 GenBank Accession Number : ... N-terminal tagged fusion protein corresponding to full ... Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium ... 30% Quality Assurance: routinely evaluated by immunoblot ...
...
X-Gal, 1 g. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzymes...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
Biology Products: